Drug safety & litigation tracker

GLP-1 drugs such as Ozempic and Wegovy face thousands of lawsuits alleging severe gastrointestinal injury (gastroparesis, intestinal blockage) and, in a separate federal case, permanent vision loss (NAION).

Depo-Provera, the long-acting birth-control shot, faces thousands of lawsuits alleging that long-term use raises the risk of meningioma (a brain tumor). The FDA has added a meningioma warning to the label.

Suboxone sublingual film faces a mass tort alleging that its acidic formulation causes severe tooth decay, erosion, and tooth loss. The FDA added a dental-problems warning to mouth-dissolved buprenorphine medicines in 2022.

Tepezza, an infusion for thyroid eye disease, faces lawsuits alleging it caused permanent hearing loss and tinnitus that the label failed to adequately warn about.

Certain generic valsartan blood-pressure pills were recalled after being found contaminated with NDMA, a probable carcinogen. Lawsuits allege the contamination caused cancer. (Brand-name Diovan was not part of the recall.)

Elmiron, prescribed for interstitial cystitis (bladder pain), faces lawsuits alleging that long-term use causes pigmentary maculopathy — a form of retinal damage and vision loss.

Tens of thousands of plaintiffs allege that long-term use of Johnson & Johnson's talc-based powders, such as Johnson's Baby Powder, caused ovarian cancer or mesothelioma because the talc was allegedly contaminated with asbestos. These remain unproven allegations. As of mid-2026, the consolidated federal cases are pending in MDL 2738 in the U.S. District Court for the District of New Jersey, where the Judicial Panel on Multidistrict Litigation's report listed 68,029 actions pending as of June 1, 2026.

Singulair (montelukast) is an asthma and allergy drug that the FDA placed under a Boxed Warning on March 4, 2020 for serious mental-health (neuropsychiatric) side effects. Lawsuits allege the manufacturer failed to adequately warn that montelukast can cause neuropsychiatric injuries such as depression and suicidal thoughts and behavior. Plaintiffs' claims are unproven and no court has found that montelukast caused these injuries. As of mid-2026 the cases are coordinated in New Jersey state court (Multicounty Litigation No. 637, In Re: Singulair Litigation, Atlantic County); there is no federal MDL and no global settlement.

Thousands of plaintiffs allege that polypropylene hernia mesh devices caused chronic pain, infection, organ damage, and the need for revision surgery, and that manufacturers failed to warn of these risks. These are allegations that have not been proven in court. In the largest litigation, against C.R. Bard, parent company Becton Dickinson announced in October 2024 that it would pay more than $1 billion to resolve roughly 38,000 federal and state claims — without admitting wrongdoing.

Plaintiffs allege that the polyester-based polyurethane (PE-PUR) sound-abatement foam in recalled Philips Respironics CPAP, BiPAP, and ventilator machines can degrade and release particles and chemicals that, they claim, caused cancer and respiratory injuries. Philips recalled roughly 15 million devices worldwide beginning in June 2021 in what the FDA classified as a Class I recall, and the company has agreed to a settlement of about $1.1 billion to resolve personal-injury claims. These remain allegations; causation has not been established in court, and the settlement is not an admission of liability.

Thousands of women have sued the makers of the Paragard copper IUD, alleging the device can break apart during removal and leave fragments in the body that may require surgery to retrieve. The cases are consolidated in federal multidistrict litigation, In re: Paragard IUD Products Liability Litigation, MDL No. 2974, in the U.S. District Court for the Northern District of Georgia, where court records indicate roughly 4,071 lawsuits were pending as of June 1, 2026. These are allegations that remain unproven; the first bellwether trial ended in a defense verdict, and no court has established that Paragard causes the alleged injuries.

Thousands of women allege in federal court that long-term use of chemical hair relaxers and straighteners caused uterine and other reproductive cancers; the cases are consolidated in MDL No. 3060 in the U.S. District Court for the Northern District of Illinois before Judge Mary M. Rowland. The claims are allegations only — no court has found that hair relaxers cause cancer, and no general settlement has been reached as of mid-2026.

Uloric (febuxostat) is a prescription gout medication. On February 21, 2019, the FDA added a Boxed Warning to Uloric after concluding, from the manufacturer's required CARES safety trial, that the drug was associated with a higher risk of cardiovascular death and death from all causes compared with allopurinol. Plaintiffs allege that Takeda failed to adequately warn of these cardiovascular risks. These are allegations, not findings of fact; as of mid-2026 the cases have been filed individually and have not been consolidated into a federal multidistrict litigation (MDL). A later trial (FAST) did not find the same increased risk, and courts have not established that Uloric caused the claimed injuries.